Biotech RadarJobs updated

COMPANY

Apogee Therapeutics

HQ: San Francisco, CA source · apogeetherapeutics.com ↗ · New England

Clinical Phase 2

Keywords: antibody dermatology respiratory Atopic Dermatitis Asthma APG777 APG990

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Partnership Partnership / licensing: upfront not published; stated deal value $1.3B (kept separate from upfront), announced May 27, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start Phase 1: An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis source ↗
  3. Trial start Phase 2: A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis source ↗
  4. Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma source ↗
  5. Trial start Phase 2: A Study Evaluating APG777 in Atopic Dermatitis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07027527An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisPhase 1Active, not recruitingJun 4, 2025Aug 29, 2026 (actual)
NCT06395948A Study Evaluating APG777 in Atopic DermatitisPhase 2Active, not recruitingApr 29, 20242026-11 (estimated)
NCT06920901A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaPhase 1Active, not recruitingMar 27, 2025Sep 17, 2026 (actual)
NCT07003425A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic DermatitisPhase 2RecruitingMay 14, 20252029-12 (estimated)
Feedback